{
    "nct_id": "NCT06287918",
    "official_title": "A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations",
    "inclusion_criteria": "* The patient is willing and able to provide written informed consent and has the ability to comply with the study protocol\n* Men or women, age ≥ 18 years at the time of signing informed consent.\n* Histologically or cytologically confirmed surgically unresectable, locally advanced, metastatic solid tumor.\n* ECOG score is 0 or 1.\n* An expected survival of ≥ 12 weeks.\n* Evaluable or measurable disease per RECIST v1.1.\n* Adequate organ function, as measured by laboratory values.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastases.\n* Have other malignancies within the past 3 years.\n* The toxicity from previous anti-tumor treatment has not recovered to ≤ grade 1.\n* Clinically significant corneal or retinal disease/keratopathy.\n* Clinically significant cardiovascular disorders.\n* Failure to swallow, chronic diarrhea, or presence of other factors affecting drug absorption.\n* Known to be allergic to any study drug or any of its excipients.\n* Any other diseases or clinical laboratory, etc that may affect the interpretation of the results, or renders the patients at high risk from treatment complications.",
    "miscellaneous_criteria": ""
}